Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2016, Article ID 7031245, 3 pages
http://dx.doi.org/10.1155/2016/7031245
Case Report

A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution

1North Alsace Mental Health Clinic (Etablissement Public de Santé Alsace Nord (EPSAN)), Brumath, France
2Psychiatry Department, University Hospital of Strasbourg, Strasbourg, France
3OMEDIT Alsace, Faculté de Pharmacie-Laboratoire HuManiS (EA 7308), Service Pharmacie-CHRU de Strasbourg, Strasbourg, France

Received 4 July 2016; Revised 23 August 2016; Accepted 26 September 2016

Academic Editor: Toshiya Inada

Copyright © 2016 Edwige Heitzmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Peña, T. C. Yaltho, and J. Jankovic, “Tardive dyskinesia and other movement disorders secondary to aripiprazole,” Movement Disorders, vol. 26, no. 1, pp. 147–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. H. S. Duggal, “Aripiprazole-induced improvement in tardive dyskinesia,” Canadian Journal of Psychiatry, vol. 48, no. 11, pp. 771–772, 2003. View at Google Scholar · View at Scopus
  3. L. Lykouras, E. Rizos, and R. Gournellis, “Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 31, no. 7, pp. 1535–1536, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Caykoylu, O. Ekinci, and E. Yilmaz, “Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 33, no. 3, pp. 571–572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Schwartz and S. Raza, “Aripiprazole (ability) and tardive dyskinesia,” Pharmacy and Therapeutics, vol. 33, no. 1, pp. 32–34, 2008. View at Google Scholar · View at Scopus
  6. C. R. Dolder and D. V. Jeste, “Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients,” Biological Psychiatry, vol. 53, no. 12, pp. 1142–1145, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. W. Woods, H. Morgenstern, J. R. Saksa et al., “Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A Prospective Cohort Study,” Journal of Clinical Psychiatry, vol. 71, no. 4, pp. 463–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Mamo, A. Graff, R. Mizrahi, C. M. Shammi, F. Romeyer, and S. Kapur, “Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study,” American Journal of Psychiatry, vol. 164, no. 9, pp. 1411–1417, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Murphy, S. Dursun, S. McKie, R. Elliott, and J. F. W. Deakin, “An investigation into aripiprazole’s partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers,” Psychopharmacology, vol. 233, no. 8, pp. 1415–1426, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. L. S. Kegeles, M. Slifstein, W. G. Frankle et al., “Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F] fallypride,” Neuropsychopharmacology, vol. 33, no. 13, pp. 3111–3125, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. S. Peña, T. C. Yaltho, and J. Jankovic, “Tardive dyskinesia and other movement disorders secondary to aripiprazole,” Movement Disorders, vol. 26, no. 1, pp. 147–152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. A. De Bartolomeis, C. Tomasetti, and F. Iasevoli, “Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism,” CNS Drugs, vol. 29, no. 9, pp. 773–799, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Goyal and S. H. Devi, “A case of aripiprazole induced tardive dyskinesia in a neuroleptic-naïve patient with two years of follow up,” Clinical Psychopharmacology and Neuroscience, vol. 12, no. 1, pp. 69–71, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Sato, K. Yoshida, and H. Higuchi, “Probable aripiprazole-induced tardive writer's cramp,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 24, no. 3, article E44, 2012. View at Google Scholar · View at Scopus
  15. J. Alexander and S. Bickerstaff, “Aripiprazole induced tardive dyskinesia—accruing evidence,” Australian and New Zealand Journal of Psychiatry, vol. 47, no. 3, pp. 289–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. N. B. Tomruk, O. Saatcioglu, E. Yildizhan, and N. Alpay, “Aripiprazole-induced tardive dyskinesia treated with quetiapine: a case report,” Acta Neuropsychiatrica, vol. 23, no. 4, pp. 188–190, 2011. View at Publisher · View at Google Scholar · View at Scopus